---

---

for   tags : Positive   

save search

---

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| Email alert Add to watchlist
NVSEF | News | $95.11 6.88% 490 |

Health Technology

| Email alert Add to watchlist
malaria positive treatment for novartis

---

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -0.11% | O: -0.11% H: 0.0% C: 0.0%
NBIX | News M | $140.11 4.83% 4.6% 1.6M |

Health Technology

| 4.81% | O: 5.49% H: 2.84% C: -0.65%
nbi-1065 positive for

---

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
SILO | $1.8 -9.55% -10.56% 5.2M |

Finance and Insurance

| -9.18% | O: 9.18% H: 0.47% C: -16.82%
pharma positive treatment for results

---

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.99 4.02% 3.86% 26K |

Health Technology

| 37.47% | O: 5.41% H: 41.06% C: 29.66%
bb-301 first positive biopharma for trial opmd study

---

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.99 -0.26% -0.26% 1.4M |

Finance

| 1.02% | O: 0.78% H: 0.0% C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living

---

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | News | $5.0 -1.48% -1.5% 2.3M |

Health Technology

| -37.19% | O: -5.78% H: 0.0% C: 0.0%
ocular positive for topline diabetic

---

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.53 9.05% 8.3% 72K |

Health Technology

| 7.73% | O: -6.87% H: 0.0% C: 0.0%
tacti-004 lung positive cancer cell for trial

---

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.68 4.58% 4.38% 610K |

| -13.17% | O: 9.85% H: 4.63% C: -18.04%
fda positive pharmaceuticals for technology response

---

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN | $18.595 0.57% 0.56% 510K |

Health Technology

| -2.97% | O: -2.61% H: 0.0% C: 0.0%
prequel positive for study

---

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.015 -1.46% -1.48% 120K |

Health Technology

| -1.0% | O: 64.34% H: 4.82% C: -18.67%
fxr314 metabolic liver positive for results

---

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.24 0.0% 6.9M |

Health Technology

| -29.82% | O: 2.92% H: 3.41% C: 2.27%
ocu400 approval positive for therapy

---

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K |

Health Technology

| -21.96% | O: 2.36% H: 6.6% C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy

---

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.365 9.97% 9.06% 240K |

Health Technology

| -7.65% | O: 2.19% H: 6.15% C: 5.35%
metabolic positive for meeting hypertension therapeutics study

---

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -0.88% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

---

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.955 9.9% 9.01% 410K |

| -80.13% | O: -65.69% H: 0.84% C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting

---

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.98 0.25% 0.25% 310K |

n/a

| 6.97% | O: 0.36% H: 0.18% C: -2.76%
ocs-01 positive treatment for meeting trial results

---

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $41.85 1.9% 1.86% 630K |

Health Technology

| Email alert Add to watchlist
positive for results study

---

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Published: 2024-04-05 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.24 0.0% 6.9M |

Health Technology

| -23.08% | O: 1.92% H: 0.0% C: 0.0%
ocu410 armada review positive for study

---

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.635 4.77% 4.55% 380K |

Health Care and Social Assistan...

| -13.53% | O: 1.34% H: 0.0% C: -4.21%
bt-600 positive trial therapeutics results platform

---

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K |

Health Technology

| -4.05% | O: -1.3% H: 0.7% C: 0.36%
pruritus positive livmarli

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---